In my last post, I covered the 1997 arrest and subsequent conviction and imprisonment of Robert Ed Forchion, also known as NJWeedman. As I write, we remain in the midst of sustained nationwide protests and an emerging public discussion about policing in the wake of the murder of George Floyd. Watching a police officer callously assault and eventually kill a man while being filmed has led to a sea change (though still severely limited) in public acknowledgement and critique of poor police behavior. But watching the subsequent coverage of the police response to this critique (which has been to double down on their brutality) keeps bringing me back to Ed Forchion, whose post-release story (though not as tragic as George Floyd’s) highlights the depths of the systemic problems of modern policing.
Editor’s Note: Today’s post comes from Dr. Suzanne Taylor, Research Fellow at the Centre for History in Public Health, London School of Hygiene & Tropical Medicine, and is based off of her presentation at the Cannabis: Global Histories conference, held at the University of Strathclyde, Glasgow, on April 19-20, 2018. In it, she explores the role of lay knowledge and social activism in transforming cannabis into a legitimate medical substance from the 1970s to today.
In March 2018, the case of Alfie Dingley, a six year old boy with epilepsy, hit the headlines as his mother campaigned for access to cannabis oil to help alleviate his seizures.  But what was the background to activism for access to cannabis on medical grounds? When cannabis-based medicine was withdrawn in the UK in 1973 it appeared that cannabis’s career as a medicine had ended, but, even as cannabis became regulated solely as an illicit drug, it was being re-medicalized. Within ten years of cannabis tinctures’ removal, synthetic cannabis-based drugs entered the clinic. However, these drugs caused serious side effects, were expensive and difficult to access, and so were little used. In the UK in the late 1990s the development of a cannabis-based drug using extracts from cannabis appeared to offer a potential way forward, and in 2006 the Home Office licensed GW Pharmaceuticals’ drug, Sativex, on a named-patient basis but it has not been widely available. In 2015 the report Regulating Cannabis for Medical Use in the UK claimed that British patients were “suffering unnecessarily” and argued for the rescheduling of cannabis to enable its prescription and facilitate research.